← Back to Search

Central Nervous System Stimulant

Adhansia XR for Attention Deficit Hyperactivity Disorder (ADHD)

Phase 4
Waitlist Available
Research Sponsored by Purdue Pharma LP
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Male and female subjects ≥4 and ≤12 years of age at the time of informed consent/assent.
Females of childbearing potential who are not pregnant and not nursing.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 12 months
Awards & highlights

Study Summary

This study is evaluating whether Adhansia XR is safe for children.

Eligible Conditions
  • Attention Deficit Hyperactivity Disorder (ADHD)

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
The Number of Participants With Adverse Events as a Measure of Safety
Secondary outcome measures
Assessment of Clinical Global Impression-Improvement (CGI-I)
Assessment of Clinical Global Impression-Severity (CGI-S)
Change from Baseline in the Attention Deficit/Hyperactivity Disorder-Rating Scale, version 5 (ADHD-RS-5) Total Score

Trial Design

1Treatment groups
Experimental Treatment
Group I: Adhansia XRExperimental Treatment1 Intervention
Adhansia XR capsules taken orally once daily in the morning

Find a Location

Who is running the clinical trial?

Purdue Pharma LPLead Sponsor
76 Previous Clinical Trials
15,133 Total Patients Enrolled
6 Trials studying Attention Deficit Hyperactivity Disorder (ADHD)
1,307 Patients Enrolled for Attention Deficit Hyperactivity Disorder (ADHD)

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~29 spots leftby Mar 2025